MarketPulse

travelers' diarrhea

2 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Not Specified

Immuron Posts Double-Digit Q3 Growth as Travelan® Expands Globally

Immuron reports Q3 sales of AUD$1.5M, up 16% YoY, with explosive 82% growth in Canada offsetting modest USA expansion.
IMRNsales growthbiopharmaceutical
GlobeNewswire Inc.GlobeNewswire Inc.··Not Specified

Immuron Lifts H1 Revenue on U.S. Growth, Pursues Partnership Strategy

Immuron lifted H1 revenue 5% to AUD$4.2M with strong U.S. growth of 17%. The company secured AUD$7.3M funding and is pursuing partnerships to advance its clinical pipeline.
IMRNFDA approvalclinical trials